Anavex Life Sciences Corp. (AVXL) Issues Quarterly Earnings Results, Meets Estimates
Anavex Life Sciences Corp. (NASDAQ:AVXL) announced its earnings results on Monday. The biotechnology company reported ($0.09) earnings per share for the quarter, meeting the consensus estimate of ($0.09), Bloomberg Earnings reports.
Shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) traded down 2.28% on Tuesday, reaching $3.85. 110,952 shares of the company traded hands. Anavex Life Sciences Corp. has a 52-week low of $2.43 and a 52-week high of $6.64. The firm has a 50-day moving average of $5.12 and a 200-day moving average of $5.47. The company’s market capitalization is $159.30 million.
Several brokerages recently weighed in on AVXL. Maxim Group set a $15.00 target price on shares of Anavex Life Sciences Corp. and gave the company a “buy” rating in a research note on Monday. ValuEngine raised shares of Anavex Life Sciences Corp. from a “sell” rating to a “hold” rating in a research note on Thursday, August 3rd. Zacks Investment Research downgraded shares of Anavex Life Sciences Corp. from a “buy” rating to a “hold” rating in a research note on Wednesday, July 12th. Finally, Noble Financial reissued a “buy” rating on shares of Anavex Life Sciences Corp. in a research note on Sunday, May 14th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $11.94.
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases.
Receive News & Ratings for Anavex Life Sciences Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences Corp. and related companies with MarketBeat.com's FREE daily email newsletter.